Sign up
Pharma Capital

Viralytics attracts funding support from Chinese life sciences company

Private placement sees Lepu Medical Group take a 13% interest.
Cancer cells
New stakeholder aims to develop a position in the Chinese oncology market

Viralytics Ltd (ASX:VLA) has received a boost for its cancer treatment development work with more than $29.6 million raised in a private placement to a leading Chinese life sciences company.

Lepu Medical Group has acquired more than 36 million shares at $0.82 each and now owns circa 13% of Viralytics.

The placement price represents a 27% premium to the 30-day volume weighted average price of Viralytics shares.

Treatments for a range of cancers

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers.

The company’s lead investigational product, CAVATAK®, is being studied in clinical trials for the treatment of melanoma, as well as bladder and lung cancers.

Lepu Medical has made the investment as part of its strategic plan to expand into the field of cancer immunotherapy.

Dr Zhongjie Pu, chairman, said: “We have carefully reviewed the global oncolytic virus landscape and believe CAVATAK is the leading agent with demonstrated potential to enhance the activity of checkpoint inhibitors such as anti-PD-1 (or PD-L1) across many important cancer types.

“We also look forward to exploring possible collaborative opportunities with Viralytics as part of our goal to develop a significant position in the Chinese oncology market.”

Cash balance of more than $50 million

The placement has taken Viralytics’ cash balance to more than $50 million with another $6.4 expected from the R&D Tax Incentive program.

It will enable the Sydney-based company to accelerate its global clinical development program.



Register here to be notified of future VLA Company articles
View full VLA profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.